TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• TG Therapeutics has received a consensus rating of "Moderate Buy" from five research firms, with an average twelve-month price target of $48.00.
• Insider Sagar Lonial sold 20,852 shares at an average price of $32.24, reflecting an 18.15% decrease in his stock ownership.
• In the most recent quarter, TG Therapeutics reported a net income margin of 13.31% but fell short of earnings expectations, with an EPS of $0.17 compared to the estimated $0.32.

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $48.00.

Several equities analysts have weighed in on the stock. The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a report on Thursday, July 10th. B. Riley boosted their target price on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the business's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. The trade was a 18.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 10.64% of the stock is owned by insiders.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TGTX. Johnson Financial Group Inc. purchased a new stake in TG Therapeutics during the 2nd quarter worth approximately $25,000. Ameritas Advisory Services LLC acquired a new position in shares of TG Therapeutics in the 2nd quarter valued at $25,000. NBC Securities Inc. boosted its holdings in shares of TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 823 shares in the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 433 shares in the last quarter. Finally, SVB Wealth LLC acquired a new position in shares of TG Therapeutics in the 1st quarter valued at $37,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

TGTX traded up $0.03 on Wednesday, reaching $32.64. 687,382 shares of the company's stock were exchanged, compared to its average volume of 2,442,985. The stock has a market cap of $5.18 billion, a PE ratio of 88.22 and a beta of 1.88. TG Therapeutics has a twelve month low of $21.16 and a twelve month high of $46.48. The stock's fifty day moving average price is $32.01 and its 200-day moving average price is $35.67. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business's revenue was up 92.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts expect that TG Therapeutics will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.